share_log

Allarity Therapeutics | RW: Registration Withdrawal Request

Allarity Therapeutics | RW: Registration Withdrawal Request

Allarity Therapeutics | RW:註冊提款請求
美股SEC公告 ·  05/09 04:10

牛牛AI助理已提取核心訊息

Allarity Therapeutics, Inc. has officially requested the withdrawal of its registration statement on Form S-1, initially filed on October 30, 2023, with the U.S. Securities and Exchange Commission (SEC). The company decided not to proceed with the public offering that the registration was meant to facilitate. The registration statement had not been declared effective by the SEC, and no securities were sold under it. Allarity Therapeutics cited the withdrawal as being in the public interest and protective of investors. The company also requested that the SEC credit the fees paid for the withdrawn registration to be used against future filings. The request for withdrawal was signed by Chief Executive Officer Thomas H. Jensen and addressed to the SEC's Division of Corporation Finance, Office of Life Sciences.
Allarity Therapeutics, Inc. has officially requested the withdrawal of its registration statement on Form S-1, initially filed on October 30, 2023, with the U.S. Securities and Exchange Commission (SEC). The company decided not to proceed with the public offering that the registration was meant to facilitate. The registration statement had not been declared effective by the SEC, and no securities were sold under it. Allarity Therapeutics cited the withdrawal as being in the public interest and protective of investors. The company also requested that the SEC credit the fees paid for the withdrawn registration to be used against future filings. The request for withdrawal was signed by Chief Executive Officer Thomas H. Jensen and addressed to the SEC's Division of Corporation Finance, Office of Life Sciences.
Alarity Therapeutics, Inc.已正式要求撤回其最初於2023年10月30日向美國證券交易委員會(SEC)提交的S-1表格的註冊聲明。該公司決定不繼續進行註冊旨在促進的公開募股。美國證券交易委員會尚未宣佈該註冊聲明生效,也沒有根據該聲明出售任何證券。Alarity Therapeutics指出,撤回符合公共利益,也保護了投資者。該公司還要求美國證券交易委員會將爲撤回的註冊所支付的費用記入貸方,用於未來的申報。撤回請求由首席執行官托馬斯·詹森簽署,並提交給美國證券交易委員會生命科學辦公室公司財務部。
Alarity Therapeutics, Inc.已正式要求撤回其最初於2023年10月30日向美國證券交易委員會(SEC)提交的S-1表格的註冊聲明。該公司決定不繼續進行註冊旨在促進的公開募股。美國證券交易委員會尚未宣佈該註冊聲明生效,也沒有根據該聲明出售任何證券。Alarity Therapeutics指出,撤回符合公共利益,也保護了投資者。該公司還要求美國證券交易委員會將爲撤回的註冊所支付的費用記入貸方,用於未來的申報。撤回請求由首席執行官托馬斯·詹森簽署,並提交給美國證券交易委員會生命科學辦公室公司財務部。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。